{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:12:39Z","timestamp":1792692759333,"version":"4.5.0"},"reference-count":21,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Birth Defects Research"],"published-print":{"date-parts":[[2021,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Preclinical studies with tofacitinib demonstrated teratogenic effects. Data about effects on human fetuses are limited and current recommendations are to immediately discontinue the treatment. Our purpose is to report a case of exposure to tofacitinib during the first trimester of pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Summary<\/jats:title><jats:p>A 40\u2010year\u2010old woman with psoriatic arthritis became pregnant during the first month of treatment with tofacitinib. Tofacitinib was interrupted immediately, and parents were informed about the possible risks of teratogenicity. At the end of pregnancy, our patient gave birth to a healthy newborn.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>All the available evidence of tofacitinib exposure during pregnancy in humans belongs to outcomes of unexpected pregnancies in the context of clinical trials and post\u2010marketing cases. This case may contribute to enriching available data about teratogenic risks of tofacitinib exposure during pregnancy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bdr2.1942","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T11:34:40Z","timestamp":1627299280000},"page":"1275-1279","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Fetal exposure to tofacitinib during the first trimester: A\u00a0healthy newborn case report"],"prefix":"10.1002","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-2033","authenticated-orcid":false,"given":"Mireya","family":"Fern\u00e1ndez\u2010S\u00e1nchez","sequence":"first","affiliation":[{"name":"Pharmacy Service Hospital Universitario y Polit\u00e9cnico La Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Ribes\u2010Artero","sequence":"additional","affiliation":[{"name":"Pharmacy Service Hospital Universitario y Polit\u00e9cnico La Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Rom\u00e1\u2010S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Pharmacy Service Hospital Universitario y Polit\u00e9cnico La Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Rosa","family":"G\u00f3mez\u2010Portero","sequence":"additional","affiliation":[{"name":"Gynecology Service Hospital Universitario y Polit\u00e9cnico La Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Guerrero\u2010Hurtado","sequence":"additional","affiliation":[{"name":"Pharmacy Service Hospital Universitario y Polit\u00e9cnico La Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda\u2010Pellicer","sequence":"additional","affiliation":[{"name":"Pharmacy Service Hospital Universitario y Polit\u00e9cnico La Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Poveda\u2010Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Pharmacy Service Hospital Universitario y Polit\u00e9cnico La Fe  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1541739"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.31778"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-016-0431-z"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.054940"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1184973"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1525293"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0240-8"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01346-4"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2020.96294"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208840"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000705436.64452.7d"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy160"},{"issue":"2","key":"e_1_2_6_15_1","first-page":"131","article-title":"Fetal exposure to dasatinib in a pregnant woman with chronic myeloid leukemia","volume":"15","author":"Meg\u00edas\u2010Vericat J. E.","year":"2013","journal-title":"Atencion Farmaceutica"},{"key":"e_1_2_6_16_1","volume-title":"The developing human: Clinically oriented embryology","author":"Moore K.","year":"2019"},{"key":"e_1_2_6_17_1","unstructured":"Pfizer Inc. (2019). Xeljanz prescribing information. Retrieved fromhttp:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed March 5 2020."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01141-w"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-019-1448-y"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1297-319X(19)30154-X"},{"issue":"3","key":"e_1_2_6_21_1","first-page":"1","article-title":"IBD in pregnancy: Recent advances, practical management","volume":"12","author":"Selinger C. P.","year":"2020","journal-title":"Frontline Gastroenterology"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2019.05.066"}],"container-title":["Birth Defects Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdr2.1942","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bdr2.1942","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdr2.1942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:31:05Z","timestamp":1693355465000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdr2.1942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2021,10,15]]}},"alternative-id":["10.1002\/bdr2.1942"],"URL":"https:\/\/doi.org\/10.1002\/bdr2.1942","archive":["Portico"],"relation":{},"ISSN":["2472-1727","2472-1727"],"issn-type":[{"value":"2472-1727","type":"print"},{"value":"2472-1727","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"2021-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}